Why Liquidia Stock Was Diving This Week
Key Points
The shares had risen by 155% year-to-date prior to earnings.
Regardless, its one commercialized drug is doing well by any measure.
- 10 stocks we like better than Liquidia ›
Liquidia (NASDAQ: LQDA) hasn't been the healthiest healthcare stock on the exchange over the past few days. On Wednesday, the commercial-stage biotech published a quarterly earnings report that led to a pronounced sell-off; as of early Friday morning, its shares were down by 20% week to date.
Yutrepia for the win
In its second quarter, Liquidia's revenue totaled almost $171.7 million, far higher than the $8.8 million it posted in the same period of 2025. That sharp rise was due almost entirely to increases in sales volume of the company's lone commercialized drug, the pulmonary hypertension treatment Yutrepia, which hit the market in June of that year.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
On the bottom line, Liquidia flipped to a net profit under generally accepted accounting principles (GAAP) of $74.7 million ($0.74 per share), from the year-ago loss of $41.6 million.
Although the company edged past the consensus analyst estimate of just under $171 million, it slightly missed the $0.76-per-share net income forecast.
Liquidia updated the progress of its one remaining developmental program, that for L-606. This medication uses the same molecule as Yutrepia and targets the same affliction. However, it has a different formulation and delivery method.
Inflated expectations
That bottom-line miss barely counts as a miss at all, given its tiny size. What happened with Liquidia was that its stock had risen so steeply -- it was up 155% year-to-date prior to earnings -- that nothing short of a crushing, blowout quarter would have sustained the momentum.
The only other concern apparent to me is the potential one-trick pony aspect of Liquidia's one favored molecule. So far, though, Yutrepia is doing quite well, and this company has a brighter future than that post-earnings decline would suggest.
Should you buy stock in Liquidia right now?
Before you buy stock in Liquidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Liquidia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $400,209!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,375,393!*
Now, it’s worth noting Stock Advisor’s total average return is 964% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of August 14, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
